Silence Therapeutics (DE:XRP2)
FRANKFURT:XRP2
Total Valuation
Silence Therapeutics has a market cap or net worth of €230.78M. The enterprise value is €259.21M.
Market Cap€230.78M
Enterprise Value€259.21M
Share Statistics
Silence Therapeutics has 47,233,948 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,233,948
Owned by Insiders22.15%
Owned by Institutions32.28%
Financial Efficiency
Silence Therapeutics’s return on equity (ROE) is -1.42 and return on invested capital (ROIC) is -70.05%.
Return on Equity (ROE)-1.42
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-70.05%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee4.82K
Profits Per Employee-763.90K
Employee Count116
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Silence Therapeutics is ―. Silence Therapeutics’s PEG ratio is 0.16.
PE Ratio―
PS Ratio513.72
PB Ratio4.61
Price to Fair Value4.61
Price to FCF-4.61
Price to Operating Cash Flow-4.35
PEG Ratio0.16
Income Statement
In the last 12 months, Silence Therapeutics had revenue of 559.00K and earned -88.61M in profits. Earnings per share was -1.89.
Revenue559.00K
Gross Profit344.00K
Operating Income-82.48M
Pretax Income-88.60M
Net Income-88.61M
EBITDA-89.20M
Earnings Per Share (EPS)-1.89
Cash Flow
In the last 12 months, operating cash flow was -62.27M and capital expenditures -110.00K, giving a free cash flow of -62.38M billion.
Operating Cash Flow-62.27M
Free Cash Flow-62.38M
Free Cash Flow per Share-1.32
Dividends & Yields
Silence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change173.26%
50-Day Moving Average4.46
200-Day Moving Average4.76
Relative Strength Index (RSI)50.57
Average Volume (3m)78.00
Important Dates
Silence Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Silence Therapeutics as a current ratio of 8.72, with Debt / Equity ratio of -0.26%
Current Ratio8.72
Quick Ratio8.72
Debt to Market Cap>-0.01
Net Debt to EBITDA0.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Silence Therapeutics has paid 11.00K in taxes.
Income Tax11.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Silence Therapeutics EV to EBITDA ratio is -3.09, with an EV/FCF ratio of -4.42.
EV to Sales493.26
EV to EBITDA-3.09
EV to Free Cash Flow-4.42
EV to Operating Cash Flow-4.43
Balance Sheet
Silence Therapeutics has €85.11M in cash and marketable securities with -€160.00K in debt, giving a net cash position of €85.27M billion.
Cash & Marketable Securities€85.11M
Total Debt-€160.00K
Net Cash€85.27M
Net Cash Per Share€1.81
Tangible Book Value Per Share€1.09
Margins
Gross margin is 61.54%, with operating margin of -16055.99%, and net profit margin of -15851.88%.
Gross Margin61.54%
Operating Margin-16055.99%
Pretax Margin-15849.91%
Net Profit Margin-15851.88%
EBITDA Margin-15956.71%
EBIT Margin-14755.33%
Analyst Forecast
The average price target for Silence Therapeutics is €29.79, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€29.79
Price Target Upside525.93% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast―